Michael S. Kay, MD, PhD

Journal Article

1. Francis JN, Redman JS, Eckert DM, Kay M (2012). Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjugate chemistry, 23(6), 1252-8. (Read full article)
2. Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay M (2015). Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets. Protein science, 24(4), 446-63. (Read full article)
3. Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia J (2011). One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. Journal of virology, 85(15), 7582-93.
4. Weinstock MT, Jacobsen MT, Kay M (2014). Synthesis and folding of a mirror-image enzyme reveals ambidextrous chaperone activity. Proceedings of the National Academy of Sciences of the United States of America, 111(32), 11679-84. (Read full article)
5. Pang HB, Hevroni L, Kol N, Eckert DM, Tsvitov M, Kay MS, Rousso (2013). Virion stiffness regulates immature HIV-1 entry. Retrovirology, 10, 4. (Read full article)
6. Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold B (2013). Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology, 10(1), 113. (Read full article)